Patents by Inventor Takako Takakuwa

Takako Takakuwa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Histamine H3 receptor agents, preparation and therapeutic uses
    Patent number: 8178528
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: May 15, 2012
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Takako Takakuwa, Cynthia Darshini Jesudason, Robert Alan Gadski, William Joseph Hornback, Richard Todd Pickard, Lisa Selsam Beavers
  • Thiazole pyrazolopyrimidines CRF1 receptor antagonists
    Patent number: 8030304
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
    Type: Grant
    Filed: September 17, 2007
    Date of Patent: October 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Chafiq Hamdouchi Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Jason Kenneth Myers, Takako Takakuwa, James Lee Toth
  • Histamine H3 receptor agents, preparation and therapeutic uses
    Patent number: 8008296
    Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I).
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: August 30, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Histamine H3 receptor agents, preparation and therapeutic uses
    Patent number: 8008301
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: August 30, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Terry Patrick Finn, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Pyrrolidine derivatives as histamine H3 receptor antagonists
    Patent number: 7951826
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: May 31, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, Cynthia Darshini Jesudason, Richard Todd Pickard, Freddie Craig Stevens, Takako Takakuwa
  • Thiazole pyrazolopyrimidines CRF1 receptor antagonists
    Publication number: 20100222339
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
    Type: Application
    Filed: September 17, 2007
    Publication date: September 2, 2010
    Inventors: Zhaogen Chen, Chafiq Hamdouchi Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Jason Kenneth Myers, Takako Takakuwa, James Lee Toth
  • HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
    Publication number: 20100160319
    Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: June 28, 2006
    Publication date: June 24, 2010
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
    Publication number: 20100160406
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: March 28, 2006
    Publication date: June 24, 2010
    Inventors: Philip Arthur Hipskind, Takako Takakuwa, Cynthia Darshini Jesudason, Robert Alan Gadski, William Joseph Hornback, Richard Todd Pickard, Lisa Selsman Beavers
  • Histamine H3 receptor agents, preparation and therapeutic uses
    Patent number: 7705025
    Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: April 27, 2010
    Assignee: Eli Lilly and Company
    Inventors: Don Richard Finley, Terry Patrick Finn, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Takako Takakuwa
  • HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
    Publication number: 20100048580
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds.
    Type: Application
    Filed: November 2, 2009
    Publication date: February 25, 2010
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Terry Patrick Finn, Robert Alan Gadski, Philip Arthur Hipskind, Wiliam Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Histamine H3 Receptor Agents, Preparation and Therapeutic Uses
    Publication number: 20100029608
    Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-113 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: October 13, 2009
    Publication date: February 4, 2010
    Inventors: Don Richard FINLEY, Terry Patrick FINN, Philip Arthur HIPSKIND, William Joseph HORNBACK, Cynthia Darshini Jesudason, Takako TAKAKUWA
  • Imidazopyridazine compounds
    Patent number: 7612067
    Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: November 3, 2009
    Assignee: Eli Lilly and Company
    Inventors: Heather Janelle Barbosa, Elizabeth Aaron Collins, Chafiq Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Richard Duane Johnston, Jianliang Lu, Michael John Rupp, Takako Takakuwa, Richard Craig Thompson
  • Imidazopyridazine compounds
    Patent number: 7557103
    Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
    Type: Grant
    Filed: April 3, 2006
    Date of Patent: July 7, 2009
    Assignee: Eli Lilly and Company
    Inventors: Elizabeth Aaron Collins, Pablo Garcia-Losada, Chafiq Hamdouchi, Philip Arthur Hipskind, Jianliang Lu, Takako Takakuwa
  • HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
    Publication number: 20090048225
    Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: August 15, 2005
    Publication date: February 19, 2009
    Inventors: Don Richard Finley, Terry Patrick Finn, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Takako Takakuwa
  • Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists
    Publication number: 20080207732
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: March 13, 2006
    Publication date: August 28, 2008
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, Cynthia Darshini Jesudason, Richard Todd Pickard, Freddie Craig Stevens, Takako Takakuwa
  • Imidazopyridazine Compounds
    Publication number: 20080153828
    Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
    Type: Application
    Filed: April 3, 2006
    Publication date: June 26, 2008
    Inventors: Elizabeth Aaron Collins, Pablo Garcia-Losada, Chafiq Hamdouchi, Philip Arthur Hipskind, Jianliang Lu, Takako Takakuwa
  • Imidazopyridazine Compounds
    Publication number: 20080113978
    Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
    Type: Application
    Filed: March 20, 2006
    Publication date: May 15, 2008
    Inventors: Heather Janelle Barbosa, Elizabeth Aaron Collins, Chafip Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Richard Duane Johnston, Jianliang Lu, Michael John Rupp, Takako Takakuwa, Richard Craig Thompson
  • Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
    Patent number: 7314937
    Abstract: The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: January 1, 2008
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Robert Alan Gadski, Philip Arthur Hipskind, Craig William Lindsley, Karen Lynn Lobb, James Arthur Nixon, Richard Todd Pickard, John Mehnert Schaus, Takako Takakuwa, Brian Morgan Watson
  • HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
    Publication number: 20070208024
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds.
    Type: Application
    Filed: March 25, 2005
    Publication date: September 6, 2007
    Inventors: Lisa Beavers, Don Finley, Terry Finn, Robert Gadski, Philip Hipskind, William Hornback, Cynthia Jesudason, Richard Pickard, Takako Takakuwa, Grant Vaught
  • Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
    Publication number: 20040110748
    Abstract: The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: September 18, 2003
    Publication date: June 10, 2004
    Inventors: Lisa Selsam Beavers, Robert Alan Gadski, Philip Arthur Hipskind, Craig William Lindsley, Karen Lynn Lobb, James Arthur Nixon, Richard Todd Pickard, John Mehnert Schaus, Takako Takakuwa, Brian Morgan Watson